[Federal Register Volume 85, Number 94 (Thursday, May 14, 2020)]
[Notices]
[Pages 28966-28967]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-10303]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Development and 
Commercialization of Logic-Gated Chimeric Antigen Receptor (CAR) 
Therapies for the Treatment of Cluster of Differentiation 33 (CD33) 
Expressing Cancers

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patents and Patent Applications listed in 
the Supplementary Information section of this Notice to Senti Bio 
(``Senti''), located in South San Francisco, CA.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before June 15, 2020 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: Jim Knabb, Senior Technology Transfer Manager, 
NCI Technology Transfer Center, 9609

[[Page 28967]]

Medical Center Drive, RM 1E530, MSC 9702, Bethesda, MD 20892-9702 (for 
business mail), Rockville, MD 20850-9702; Telephone: (240)-276-7856; 
Facsimile: (240)-276-5504; Email: [email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

E-097-2018-0: Anti-CD33 Chimeric Antigen Receptors for Treatment of 
Human Acute Myeloid Leukemia

    1. U.S. Provisional Patent Application 62/643,015, filed March 14, 
2018 (E-097-2018-0-US-01);
    2. International Patent Application PCT/US2019/022,309, filed March 
14, 2019 (E-097-2018-0-PCT-02)

    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the fields of use may be limited to the following:
    An exclusive license to:
    1. The development of a CD33-specific logic-gated CAR-based 
immunotherapy using autologous human T cells transduced with lentiviral 
vectors, wherein the viral transduction leads to the expression of a 
CAR that targets CD33 (comprised of the CD33-binding domain referenced 
as Hu195 or hP67.6 in the invention as well as an intracellular 
signaling domain), for the prophylaxis or treatment of CD33-expressing 
cancers. For clarity, ``CD33-specific logic-gated CAR-based 
immunotherapy'' means therapies where the CAR-expressing T cells 
recognize CD33 and are engineered to respond to one or more additional 
antigens (but not necessarily all of the signals).
    2. The development of a CD33-specific logic-gated CAR-based 
immunotherapy using allogeneic human NK cells transduced with 
lentiviral vectors, wherein the viral transduction leads to the 
expression of a CAR that targets CD33 (comprised of the CD33-binding 
domain referenced as Hu195 or hP67.6 in the invention as well as an 
intracellular signaling domain), for the prophylaxis or treatment of 
CD33-expressing cancers. For clarity, ``CD33-specific logic-gated CAR-
based immunotherapy'' means therapies where the CAR-expressing NK cells 
recognize CD33 and are engineered to respond to one or more additional 
antigens (but not necessarily all of the signals).
    This technology discloses a CAR therapy that targets CD33 by 
utilizing the anti-CD33 binder known as Hu195 or hP67.6 for the 
treatment of hematological malignancies. CD33 is a validated 
immunotherapeutic target that is expressed on the surface of the vast 
majority of acute myelogenous leukemia (AML) blasts and cells in 
chronic myeloid leukemia-blast crisis (CML-BC).
    This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
thirty (30) days from the date of this published Notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information from these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: May 7, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2020-10303 Filed 5-13-20; 8:45 am]
BILLING CODE 4140-01-P